Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort

This real-world study confirms carfilzomib effectiveness at both dosing frequencies. K triplets resulted in long survivals and Kd remained satisfactory to treat heavily pretreated patients.

Authors

Institutions

Publication Details

Journal
Clinical Lymphoma Myeloma & Leukemia
Published
2025-08-08
DOI
https://doi.org/10.1016/j.clml.2025.08.002
Citations
1
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
1.77

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort

Karim Belhadj Merzoug, Olivier Decaux, Ronan Garlantézec, Lionel Karlin et al.
1 citations
Clinical Lymphoma Myeloma & Leukemia
Multiple Myeloma Research and Treatments
1.77
article

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort

Karim Belhadj Merzoug, Olivier Decaux, Ronan Garlantézec, Lionel Karlin, Claire Calmettes, Riad Benramdane, Arthur Bobin, Hakima Mechiche, Gaëlle Désaméricq, Margaret Macro, Laure Vincent, Thomas Chalopin, Bruno Royer, Aurore Perrot, Cyrille Hulin, Laurent Frenzel, Mohamad Mohty, Mammoun Dib, Denis Caillot, Frédérique Orsini Piocell
article en
1 citations

Abstract

This real-world study confirms carfilzomib effectiveness at both dosing frequencies. K triplets resulted in long survivals and Kd remained satisfactory to treat heavily pretreated patients.

Clinical Lymphoma Myeloma & LeukemiaVol. 26(1)
Université de Tours (FR), Université Paris-Est Créteil (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Université Rennes 2 (FR), Université de Poitiers (FR), Sorbonne Université (FR), Hospital for Sick Children Pediatric Center (US), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Hôpital Lyon Sud (FR), Centre Hospitalier Annecy Genevois (FR), Centre de Recherche Saint-Antoine (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpital Saint-Louis (FR), Centre Hospitalier René-Dubos (FR), Lymphoma Study Association (FR), Lux Research (United States) (US), Université d'Angers (FR), Université de Rennes (FR), Chiesi (France) (FR), Université de Caen Normandie (FR)
Amgen
Openalex Percentile: Top 13%
Multiple Myeloma Research and Treatments
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.